Literature DB >> 9202408

Rhamnogalacturonan II from the leaves of Panax ginseng C.A. Meyer as a macrophage Fc receptor expression-enhancing polysaccharide.

K S Shin1, H Kiyohara, T Matsumoto, H Yamada.   

Abstract

A complex pectic polysaccharide (GL-4IIb2) has been isolated from the leaves of Panax ginseng C.A. Meyer, and shown to be a macrophage Fc receptor expression-enhancing polysaccharide. The primary structure of GL-4IIb2 was elucidated by composition. 1H NMR, methylation, and oligosaccharide analyses. GL-4IIb2 consisted of 15 different monosaccharides which included rarely observed sugars, such as 2-O-methylfucose, 2-O-methylxylose, apiose, 3-C-carboxy-5-deoxy-L-xylose (aceric acid, AceA), 3-deoxy-D-manno-2-octulosonic acid (Kdo), and 3-deoxy-D-lyxo-2-heptulosaric acid (Dha). Methylation analysis indicated that GL-4IIb2 comprised 34 different glycosyl linkages, such as 3,4-linked Fuc, 3- and 2,3,4-linked Rha, and 2-linked GlcA, which are characteristic of rhamnogalacturonan II (RG-II). Sequential degradation using partial acid hydrolysis indicated that GL-4IIb2 contained alpha-Rhap-(1-->5)-Kdo and Araf-(1-->5) Dha structural elements, an AceA-containing oligosaccharide, and uronic acid-rich oligosaccharide chains in addition to an alpha-(1 -->4)-galacturono-oligosaccharide chain. FABMS and methylation analyses suggested that the AceA-containing oligosaccharide was a nonasaccharide in which terminal Rha was additionally attached to position 3 of 2-linked Arap of the octasaccharide chain observed in sycamore RG-II. Component sugar and methylation analyses assumed that the uronic acid-rich oligosaccharides possessed a similar structural feature as those in sycamore RG-II. GL-4IIb2 had a larger molecular mass (11,000) than sycamore RG-II (approximately 5000).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202408     DOI: 10.1016/s0008-6215(97)00055-4

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  7 in total

1.  Efficacy of an extract of North American ginseng containing poly-furanosyl-pyranosyl-saccharides for preventing upper respiratory tract infections: a randomized controlled trial.

Authors:  Gerald N Predy; Vinti Goel; Ray Lovlin; Allan Donner; Larry Stitt; Tapan K Basu
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

2.  An NMR solution study of the mega-oligosaccharide, rhamnogalacturonan II.

Authors:  C Hervé du Penhoat; C Gey; P Pellerin; S Perez
Journal:  J Biomol NMR       Date:  1999-07       Impact factor: 2.835

3.  Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management of the common cold.

Authors:  Mostafa Yakoot; Amel Salem
Journal:  Int J Gen Med       Date:  2011-01-12

4.  A placebo-controlled trial of Korean red ginseng extract for preventing influenza-like illness in healthy adults.

Authors:  Ki-Chan Ha; Min-Gul Kim; Mi-Ra Oh; Eun-Kyung Choi; Hyang-Im Back; Sun-Young Kim; Eun-Ok Park; Dae-Young Kwon; Hye-Jeong Yang; Min-Jeong Kim; Hee-Joo Kang; Ju-Hyung Lee; Kyung-Min Choi; Soo-Wan Chae; Chang-Seop Lee
Journal:  BMC Complement Altern Med       Date:  2012-02-08       Impact factor: 3.659

5.  Green synthesis of metallic nanoparticles using pectin as a reducing agent: a systematic review of the biological activities.

Authors:  Kogilavanee Devasvaran; Vuanghao Lim
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

6.  Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

Authors:  Sung Nam Park; Kyung Tae Noh; Young-Il Jeong; In Duk Jung; Hyun Kyu Kang; Gil Sun Cha; Su Jung Lee; Jong Keun Seo; Dae Hwan Kang; Tae-Ho Hwang; Eun Kyung Lee; Byungsuk Kwon; Yeong-Min Park
Journal:  Exp Mol Med       Date:  2013-02-08       Impact factor: 8.718

Review 7.  Development of Broad-Spectrum Antiviral Agents-Inspiration from Immunomodulatory Natural Products.

Authors:  Mengxun Zhang; Jiaqing Zhong; Yongai Xiong; Xun Song; Chenyang Li; Zhendan He
Journal:  Viruses       Date:  2021-06-28       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.